Merck & Co., Inc.

Merck & Co., Inc.

MRKNYSE / NASDAQHealthcareLarge cap

$133.72+$0.91 (+0.7%)

Last close · Data as of Nov 20, 2026

Market cap
$297.0B
P/E
16.3x
EV / EBITDA
11.7x
Revenue
$65.0B
Net margin
28.1%
ROCE
20.4%

+40.8% over the last year

Merck & Co., Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-9.8%
3M
-10.2%
6M
+18.3%
1Y
+40.8%
5Y
+65.7%

52-week range

Day change +$0.91 (+0.7%) from $133 to $134 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MRK, bought on each weekday since 2021.

News & filings

What Merck & Co. filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity of 34.7% against a peer median of 12.7%.

Concerns (1)

  • Revenue grew 3.1% a year over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

Read moreShow less

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Sector
Healthcare
Shares outstanding
2.47B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$297.0B
P/E
16.3x
P/B
5.6x
EV / EBITDA
11.7x
EV / Sales
5.1x
P/S
4.6x
52-week high
$156.45
52-week low
$94.97

Profitability

Operating margin
34.0%
Net margin
28.1%
EBITDA margin
43.5%
ROE
34.7%
ROCE
20.4%
ROA
13.3%
Asset turnover
0.47

Growth

Revenue
$65.0B
Revenue growth, 1Y
1.3%
Revenue CAGR, 3Y
3.1%
Net profit growth, 1Y
6.6%
Free cash flow
$12.4B

Solvency

Current ratio
1.54
Debt / Equity
0.94
Debt / Assets
0.36
CFO / Net profit
0.90
Cash / Market cap
4.9%

Where the revenue went

Of every $100 of FY2025 revenue, $28 was left as net income.

Merck & Co., Inc. income statement flow, FY2025
Merck & Co., Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$16.4B
RevenueGross profit$48.6B
Gross profitResearch and development$15.8B
Gross profitSelling, general and administrative$10.7B
Gross profitOperating income$22.1B
Operating incomePretax income$21.1B
Operating incomeInterest and other expense$1.0B
Pretax incomeTax and other$2.8B
Pretax incomeNet income$18.3B

Revenue and net profit

Revenue grew 1.3% in FY2025; net profit is the dashed line.

Merck & Co., Inc. revenue and net profit by fiscal year
Merck & Co., Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$59.3B$14.5B
FY2023$60.1B$365.0M
FY2024$64.2B$17.1B
FY2025$65.0B$18.3B

Cash flows

FY2025: $16.5B from operations, $12.4B free after investment (dashed).

Merck & Co., Inc. operating and free cash flow by fiscal year
Merck & Co., Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$19.1B$14.7B
FY2023$13.0B$9.1B
FY2024$21.5B$18.1B
FY2025$16.5B$12.4B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$65.0B+1.3%1Y
EBITDA
$28.3B+9.9%1Y
Net profit
$18.3B+6.6%1Y
Cash from operations
$16.5B-23.3%1Y
Free cash flow
$12.4B-31.7%1Y
Revenue CAGR, 3Y
3.1%
Net profit CAGR, 3Y
7.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$65.0B$28.3B$18.3B$12.4B34.7%+1.3%+6.6%

Monthly returns

Month-by-month returns of MRK across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$136.9B
Liabilities$84.2B
Equity$52.7B
Paid-in capital$45.0B
Retained earnings$73.1B
Treasury stock$63.0B
Minority interest$56.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MRK highlighted.

P/E against peers

MRK trades at 16.3x earnings against a peer median of 25.5x (a 36% discount).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Merck & Co., Inc.MRKthis companyP/E ↓ discount$297.0B16.3x5.6x34.7%11.7x
AbbVie Inc.ABBV$397.4B94.9x—-128.0%26.1x
UnitedHealth Group IncorporatedUNH$360.1B29.9x3.8x12.8%18.0x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
Peer median—25.5x3.8x12.7%15.8x

Year-to-date ROI

MRK since 1 January, against earlier years.

Historical volatility

MRK's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Merck & Co., Inc. operating margin by fiscal year
Merck & Co., Inc. operating margin by fiscal year
DateOperating margin
FY202230.8%
FY20234.9%
FY202431.5%
FY202534.0%
LineFY2025
Cost of revenueCost Of Revenue$16.4B
Gross profitGross Profit$48.6B
Operating expensesOperating Expense$26.5B
Research and developmentResearch And Development$15.8B
Selling, general and administrativeSelling General And Administration$10.7B
Total expensesTotal Expenses$42.9B
Operating incomeOperating Income$22.1B
Pretax incomePretax Income$21.1B

Learn while you research

Academy chapters picked for Merck & Co., Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →